BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

718 related articles for article (PubMed ID: 1726961)

  • 1. Progress toward an artificial vaccine for HIV: identification of helper and cytotoxic T-cell epitopes and methods of immunization.
    Berzofsky JA
    Biotechnol Ther; 1991; 2(1-2):123-35. PubMed ID: 1726961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8+ CTL in vivo with peptide vaccine constructs.
    Shirai M; Pendleton CD; Ahlers J; Takeshita T; Newman M; Berzofsky JA
    J Immunol; 1994 Jan; 152(2):549-56. PubMed ID: 8283036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Broad recognition of cytotoxic T cell epitopes from the HIV-1 envelope protein with multiple class I histocompatibility molecules.
    Shirai M; Pendleton CD; Berzofsky JA
    J Immunol; 1992 Mar; 148(6):1657-67. PubMed ID: 1371784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction of peptides encompassing multideterminant clusters of human immunodeficiency virus envelope to induce in vitro T cell responses in mice and humans of multiple MHC types.
    Berzofsky JA; Pendleton CD; Clerici M; Ahlers J; Lucey DR; Putney SD; Shearer GM
    J Clin Invest; 1991 Sep; 88(3):876-84. PubMed ID: 1715888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antigenicity of HIV-derived T helper determinants in the context of carrier recombinant proteins: effect on T helper cell repertoire selection.
    Manca F; De Berardinis P; Fenoglio D; Ombra MN; Li Pira G; Saverino D; Autiero M; Lozzi L; Bracci L; Guardiola J
    Eur J Immunol; 1996 Oct; 26(10):2461-9. PubMed ID: 8898961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defining MHC class II T helper epitopes for WT1 tumor antigen.
    Kobayashi H; Nagato T; Aoki N; Sato K; Kimura S; Tateno M; Celis E
    Cancer Immunol Immunother; 2006 Jul; 55(7):850-60. PubMed ID: 16220325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dendritic cell vaccination induces cross-reactive cytotoxic T lymphocytes specific for wild-type and natural variant human immunodeficiency virus type 1 epitopes in HLA-A*0201/Kb transgenic mice.
    Abdel-Motal UM; Friedline R; Poligone B; Pogue-Caley RR; Frelinger JA; Tisch R
    Clin Immunol; 2001 Oct; 101(1):51-8. PubMed ID: 11580226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunization of mice with lipopeptides bypasses the prerequisite for adjuvant. Immune response of BALB/c mice to human immunodeficiency virus envelope glycoprotein.
    Martinon F; Gras-Masse H; Boutillon C; Chirat F; Deprez B; Guillet JG; Gomard E; Tartar A; Levy JP
    J Immunol; 1992 Nov; 149(10):3416-22. PubMed ID: 1385524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Priming with T helper cell epitope peptides enhances the antibody response to the envelope glycoprotein of HIV-1 in primates.
    Hosmalin A; Nara PL; Zweig M; Lerche NW; Cease KB; Gard EA; Markham PD; Putney SD; Daniel MD; Desrosiers RC
    J Immunol; 1991 Mar; 146(5):1667-73. PubMed ID: 1704401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Designing and engineering of DNA-vaccine construction encoding multiple CTL-epitopes of major HIV-1 antigens.
    Bazhan SI; Belavin PA; Seregin SV; Danilyuk NK; Babkina IN; Karpenko LI; Nekrasova NA; Lebedev LR; Ignatyev GM; Agafonov AP; Poryvaeva VA; Aborneva IV; Ilyichev AA
    Vaccine; 2004 Apr; 22(13-14):1672-82. PubMed ID: 15068850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human immunodeficiency virus type 1 Nef epitopes recognized in HLA-A2 transgenic mice in response to DNA and peptide immunization.
    Sandberg JK; Leandersson AC; Devito C; Kohleisen B; Erfle V; Achour A; Levi M; Schwartz S; Kärre K; Wahren B; Hinkula J
    Virology; 2000 Jul; 273(1):112-9. PubMed ID: 10891413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations.
    Ahlers JD; Pendleton CD; Dunlop N; Minassian A; Nara PL; Berzofsky JA
    J Immunol; 1993 Jun; 150(12):5647-65. PubMed ID: 8515081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineering immunogenic consensus T helper epitopes for a cross-clade HIV vaccine.
    De Groot AS; Bishop EA; Khan B; Lally M; Marcon L; Franco J; Mayer KH; Carpenter CC; Martin W
    Methods; 2004 Dec; 34(4):476-87. PubMed ID: 15542374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preferential V beta usage by cytotoxic T cells cross-reactive between two epitopes of HIV-1 gp160 and degenerate in class I MHC restriction.
    Shirai M; Vacchio MS; Hodes RJ; Berzofsky JA
    J Immunol; 1993 Aug; 151(4):2283-95. PubMed ID: 7688397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
    Borbe HC; Stuber G; Wagner R; Wolf H; Modrow S
    J Pept Sci; 1995; 1(2):109-23. PubMed ID: 9222988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a synthetic consensus sequence scrambled antigen HIV-1 vaccine designed for global use.
    Thomson SA; Jaramillo AB; Shoobridge M; Dunstan KJ; Everett B; Ranasinghe C; Kent SJ; Gao K; Medveckzy J; Ffrench RA; Ramshaw IA
    Vaccine; 2005 Sep; 23(38):4647-57. PubMed ID: 15964105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of cytotoxic T cell responses to candidate HIV-1 vaccines in HIV-1-uninfected individuals.
    McElrath MJ; Corey L; Greenberg PD
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S69-72. PubMed ID: 7865336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptide vaccines incorporating a 'promiscuous' T-cell epitope bypass certain haplotype restricted immune responses and provide broad spectrum immunogenicity.
    Kaumaya PT; Kobs-Conrad S; Seo YH; Lee H; VanBuskirk AM; Feng N; Sheridan JF; Stevens V
    J Mol Recognit; 1993 Jun; 6(2):81-94. PubMed ID: 7508238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of a MHC class I-restricted, CD8 positive cytolytic T-cell response by chimeric HIV-1 virus-like particles in vivo: implications on HIV vaccine development.
    Wagner R; Deml L; Schirmbeck R; Reimann J; Wolf H
    Behring Inst Mitt; 1994 Dec; (95):23-34. PubMed ID: 7755506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [MHC tetramers: tracking specific immunity].
    Kosor E; Gagro A; Drazenović V; Kuzman I; Jeren T; Rakusić S; Rabatić S; Markotić A; Gotovac K; Sabioncello A; Cecuk E; Kerhin-Brkljacić V; Gjenero-Margan I; Kaić B; Mlinarić-Galinović G; Kastelan A; Dekaris D
    Acta Med Croatica; 2003; 57(4):255-9. PubMed ID: 14639858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.